Literature DB >> 25416179

Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome.

Paolo Giannetti1, Marios Politis2, Paul Su3, Federico E Turkheimer4, Omar Malik3, Shiva Keihaninejad3, Kit Wu3, Adam Waldman3, Richard Reynolds3, Richard Nicholas3, Paola Piccini3.   

Abstract

The most accurate predictor of the subsequent development of multiple sclerosis in clinically isolated syndrome is the presence of lesions at magnetic resonance imaging. We used in vivo positron emission tomography with (11)C-(R)-PK11195, a biomarker of activated microglia, to investigate the normal-appearing white matter and grey matter of subjects with clinically isolated syndrome to explore its role in the development of multiple sclerosis. Eighteen clinically isolated syndrome and eight healthy control subjects were recruited. Baseline assessment included: history, neurological examination, expanded disability status scale, magnetic resonance imaging and PK11195-positron emission tomography scans. All assessments except the PK11195-positron emission tomography scan were repeated over 2 years. SUPERPK methodology was used to measure the binding potential relative to the non-specific volume, BPND. We show a global increase of normal-appearing white matter PK11195 BPND in clinically isolated syndrome subjects compared with healthy controls (P = 0.014). Clinically isolated syndrome subjects with T2 magnetic resonance imaging lesions had higher PK11195 BPND in normal-appearing white matter (P = 0.009) and their normal-appearing white matter PK11195 BPND correlated with the Expanded Disability Status Scale (P = 0.007; r = 0.672). At 2 years those who developed dissemination in space or multiple sclerosis, had higher PK11195 BPND in normal-appearing white matter at baseline (P = 0.007 and P = 0.048, respectively). Central grey matter PK11195 BPND was increased in subjects with clinically isolated syndrome compared to healthy controls but no difference was found in cortical grey matter PK11195 BPND. Microglial activation in clinically isolated syndrome normal-appearing white matter is diffusely increased compared with healthy control subjects and is further increased in those who have magnetic resonance imaging lesions. Furthermore microglial activation in clinically isolated syndrome normal-appearing white matter is also higher in those subjects who developed multiple sclerosis at 2 years. Our finding, if replicated in a larger study, could be of prognostic value and aid early treatment decisions in clinically isolated syndrome.
© The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  PK11195-PET; clinically isolated syndrome; microglia; multiple sclerosis; normal-appearing white matter

Mesh:

Substances:

Year:  2014        PMID: 25416179      PMCID: PMC4383265          DOI: 10.1093/brain/awu331

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  42 in total

1.  The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders.

Authors:  Sriram Venneti; Guoji Wang; Jason Nguyen; Clayton A Wiley
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

2.  Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.

Authors:  R N Gunn; A A Lammertsma; S P Hume; V J Cunningham
Journal:  Neuroimage       Date:  1997-11       Impact factor: 6.556

3.  PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  E Vowinckel; D Reutens; B Becher; G Verge; A Evans; T Owens; J P Antel
Journal:  J Neurosci Res       Date:  1997-10-15       Impact factor: 4.164

Review 4.  PET tracers for the peripheral benzodiazepine receptor and uses thereof.

Authors:  Pernilla J Schweitzer; Brian A Fallon; J John Mann; J S Dileep Kumar
Journal:  Drug Discov Today       Date:  2010-08-26       Impact factor: 7.851

5.  MRI only conversion to multiple sclerosis following a clinically isolated syndrome.

Authors:  D T Chard; C M Dalton; J Swanton; L K Fisniku; K A Miszkiel; A J Thompson; G T Plant; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-02       Impact factor: 10.154

6.  Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Authors:  D H Miller; B G Weinshenker; M Filippi; B L Banwell; J A Cohen; M S Freedman; S L Galetta; M Hutchinson; R T Johnson; L Kappos; J Kira; F D Lublin; H F McFarland; X Montalban; H Panitch; J R Richert; S C Reingold; C H Polman
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

7.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

Authors:  L K Fisniku; P A Brex; D R Altmann; K A Miszkiel; C E Benton; R Lanyon; A J Thompson; D H Miller
Journal:  Brain       Date:  2008-01-29       Impact factor: 13.501

8.  High field MR imaging and 1H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria.

Authors:  Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Hans H Schild; Frank Träber
Journal:  J Neurol       Date:  2007-12-20       Impact factor: 4.849

9.  Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis.

Authors:  Owain W Howell; Jon L Rundle; Anurag Garg; Masayuki Komada; Peter J Brophy; Richard Reynolds
Journal:  J Neuropathol Exp Neurol       Date:  2010-10       Impact factor: 3.685

10.  A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis.

Authors:  David Wheeler; Veera Venkata Ratnam Bandaru; Peter A Calabresi; Avindra Nath; Norman J Haughey
Journal:  Brain       Date:  2008-09-04       Impact factor: 13.501

View more
  39 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.

Authors:  Ulrike W Kaunzner; Yeona Kang; Shun Zhang; Eric Morris; Yihao Yao; Sneha Pandya; Sandra M Hurtado Rua; Calvin Park; Kelly M Gillen; Thanh D Nguyen; Yi Wang; David Pitt; Susan A Gauthier
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

3.  Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by 11C-PBR28 MR-PET.

Authors:  Valeria T Barletta; Elena Herranz; Costantina A Treaba; Russell Ouellette; Ambica Mehndiratta; Marco L Loggia; Eric C Klawiter; Carolina Ionete; Sloane A Jacob; Caterina Mainero
Journal:  Mult Scler       Date:  2019-04-11       Impact factor: 6.312

4.  Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis.

Authors:  Benedetta Bodini; Emilie Poirion; Matteo Tonietto; Charline Benoit; Raffaele Palladino; Elisabeth Maillart; Erika Portera; Marco Battaglini; Geraldine Bera; Bertrand Kuhnast; Céline Louapre; Michel Bottlaender; Bruno Stankoff
Journal:  J Nucl Med       Date:  2020-01-31       Impact factor: 10.057

Review 5.  Multiple Sclerosis and T Lymphocytes: An Entangled Story.

Authors:  Laurine Legroux; Nathalie Arbour
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-07       Impact factor: 4.147

6.  Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity.

Authors:  A Beer; V Biberacher; P Schmidt; R Righart; D Buck; A Berthele; J Kirschke; C Zimmer; B Hemmer; M Mühlau
Journal:  J Neurol       Date:  2016-05-13       Impact factor: 4.849

Review 7.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 8.  Immunopathology of multiple sclerosis.

Authors:  Calliope A Dendrou; Lars Fugger; Manuel A Friese
Journal:  Nat Rev Immunol       Date:  2015-08-07       Impact factor: 53.106

9.  Neuroinflammatory component of gray matter pathology in multiple sclerosis.

Authors:  Elena Herranz; Costanza Giannì; Céline Louapre; Constantina A Treaba; Sindhuja T Govindarajan; Russell Ouellette; Marco L Loggia; Jacob A Sloane; Nancy Madigan; David Izquierdo-Garcia; Noreen Ward; Gabriel Mangeat; Tobias Granberg; Eric C Klawiter; Ciprian Catana; Jacob M Hooker; Norman Taylor; Carolina Ionete; Revere P Kinkel; Caterina Mainero
Journal:  Ann Neurol       Date:  2016-10-25       Impact factor: 10.422

10.  Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.

Authors:  Gourab Datta; Ines R Violante; Gregory Scott; Karl Zimmerman; Andre Santos-Ribeiro; Eugenii A Rabiner; Roger N Gunn; Omar Malik; Olga Ciccarelli; Richard Nicholas; Paul M Matthews
Journal:  Mult Scler       Date:  2016-12-07       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.